Advent Pharmaceuticals Pty Ltd
ACN 43 095 494 563
Dr Jill Snell, General Manager
+61 3 8562 2235
+61 3 8562 2288
Monash Enterprise Centre5a Harnett CloseMulgrave, VIC, 3170Australia
Advent Pharmaceuticals is a technology development company specialising in the development of novel dry powder inhalation delivery platforms. The focus of Advent’s product development isdirected initially at novel platforms for the management of asthma and chronic obstructive pulmonary disease, with future therapeutic applications in new pulmonary delivered medications.Established in January 2001, Advent Pharmaceuticals is an Australian-registered, privately owned company. Advent’s product design, development and preclinical testings are presently conducted in Victoria, Australia. Clinical, regulatory and manufacturing will be outsourced to local and international contract organisations.
AgGenomics Pty. Ltd.
ACN 16 099 612 423
Dr Glenn Tong, Managing Director
+61 3 8412 7066
+61 3 9417 4076
60-66 Hanover StreetFitzroy, VIC, 3065Australia
P. O. Box 115Fitzroy, VIC, 3065Australia
AgGenomics Pty. Ltd. was formed in March 2002 as a joint venture between Genetic TechnologiesLimited (ASX-GTG) and Agriculture Victoria Services Pty Ltd (the commercial arm of the VictorianGovernment's Department of Natural Resources and Environment). This joint venture, the first ultra high throughput genomics facility in Australasia, will dramatically improve the efficiency of traditional plant and animal breeding programs via the use of ultra high throughput genomicstechnologies. AgGenomics has unique enabling technologies, expertise and extensive experience in theidentification of genetic markers linked to commercially important traits in a wide variety of plant species. The same technology is also applicable to animal species. The development of genetic markers such as SNPs, microsatellites (SSRs) and AFLPs and the application of these markers inmarker assisted selection (MAS) is AgGenomics’ key strength and primary business activity. AgGenomics has extremely high throughput capabilities, with a capacity of well over 20,000 genotype analyses per day using a suite of state-of-the-art automated technology platforms.These capabilities allow plant and animal breeders to deliver improved varieties to the market quicker and more economically through the use of MAS. AgGenomics also has expertise and experience in cultivar identification, eg for Plant Breeders’ Rights and transgene detection. AgGenomics primarily operates on a fee-for-service basis, with no participation in the sharing of intellectual property. In certain circumstances, such as genetic marker discovery programs which are linked to a marker assisted selection program requiring ultrahigh throughput genotyping, AgGenomics may also enter into collaborative R&D programs on acost and IP sharing basis.